

13 March 2006



## **PharmAust Receives TGA Licence to Manufacture Medicinal Products**

**PharmAust Limited (ASX: PAA) is pleased to announce the Therapeutic Goods Administration (TGA) has today awarded its wholly owned subsidiary PharmAust Manufacturing an unconditional licence to manufacture medicinal products for the Australian and overseas markets.**

The TGA licence allows PharmAust Manufacturing to begin manufacturing the 95 therapeutic products it currently has listed on the Australian Register of Therapeutic Goods (ARTG), along with contract manufacturing of therapeutic goods on behalf of third parties.

Based at modern facilities in Welshpool, WA, PharmAust Manufacturing already manufactures over 200 non-therapeutic products in areas such as personal care, cosmetics and galenicals.

PharmAust is embarking on a strategy to bring to the Australian market a range of over-the-counter (OTC) medicines and generic PBS prescription pharmaceuticals through its Agreement with Malaysia's Xepa-Soul Pattinson.

The preparation of applications to the TGA to register three drugs in anti-allergy and gastro-oesophageal reflux therapeutic categories is underway.

It is anticipated these applications will be the first in a series of registrations for an initial group of 10 generic medicines in five different therapeutic categories being anti-infectives, anti-virals, anti-allergy, antacid and gastro-oesophageal reflux disease.

PharmAust plans to register a further 50 products over the next three years as a number of key drug patents expire. Once approved, PharmAust will offer competitively priced generics in these categories, which have a combined market of over \$400 million.

PharmAust Managing Director Dr Paul D'Sylva said: "PharmAust is positioning itself as a key player in Australia's generic drug market, which is expected to grow to \$1.8 billion over the next three years.

"The TGA licence, along with our supply agreement with Xepa Soul-Pattinson and distribution agreement with Cottmans, will support PharmAust in its strategy to be one of the top five generic drug market players by 2008.

"Our goal is to provide low cost, high quality and timely products for pharmacists and hospitals," he said.

PharmAust Manufacturing CEO Dr John Moursounidis said the TGA licence was the last major hurdle to clear before implementing the Company's generics strategy.

"We've all worked very hard to achieve this milestone – and we are looking forward to the next phase of growth for PharmAust Manufacturing," he said.

**Further comments**  
**Dr Paul D'Sylva**  
**Managing Director, PharmAust Limited**  
**P: (03) 9565 1111**  
**M: 0410 602 586**

**Media Enquiries:**  
**Sarah Allchurch**  
**Allchurch Communications**  
**P: (08) 9381 6625**  
**M: 0412 346 412**

## **About PharmAust Limited**

PharmAust Limited is a vertically integrated pharmaceutical Group of companies involved in a range of activities from contract drug discovery and development to manufacturing, sales and marketing of healthcare & pharmaceutical products.

PharmAust wholly owns three main operating subsidiary companies:

**PharmAust Manufacturing Pty Ltd** manufactures and markets therapeutic and non-therapeutic pharmaceutical products for Australian and overseas markets.

**Epichem Pty Ltd** provides contract chemistry services alongside its own intellectual property generating research activities.

**Mimotopes Pty Ltd** provides products and services in discovery peptide chemistry to the global pharmaceutical and biotechnology industries.